News Releases

 
News Releases
  Date Title and Summary View
May 13, 2008
Mountain View, CA - May 13, 2008 - ChemoCentryx, Inc., today announced the initiation of a Phase I clinical trial of CCX354, an orally-available, novel small molecule compound designed to specifically target the CCR1 chemokine receptor which is associated with inflammatory diseases such as rheumatoid arthritis. With the dosing of t...
Jan 17, 2008
Mountain View, CA - January 17, 2008 - ChemoCentryx, Inc. today announced the appointment of Edward E. Penhoet, Ph.D., to the company's Board of Directors. Dr. Penhoet is recognized for his 25 years of leadership and contributions in the public and private sectors of the life sciences industry, including as co-founder and Chief Exe...
Sep 26, 2007
Mountain View, CA - September 26, 2007 - ChemoCentryx, Inc., a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing therapeutics that target the chemokine system, today announced the publication of data from a series of rigorous experiments to elucidate CXCR7's essential role in the progression a...
Jul 24, 2007
Mountain View, CA - July 24, 2007 - ChemoCentryx, Inc., a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing orally-administered therapeutics that target the chemokine system, today announced that it has earned a $5 million milestone payment from GlaxoSmithKline (NYSE: GSK) for progress in its sma...
May 23, 2007
Mountain View, CA - May 23, 2007 — ChemoCentryx, Inc., a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing orally-administered therapeutics that target the chemokine system, presented data today from the company's Phase 2 clinical trial of Traficet-EN™ (CCX282-B), an orally...
May 17, 2007
Mountain View, CA - May 17, 2007 — ChemoCentryx, Inc., a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing orally-administered therapeutics that target the chemokine system, announced that data from the company's Phase 2 clinical trial of Traficet-EN™ (CCX282-B), targeting ...
Jan 4, 2007
Mountain View, CA - January 4, 2007 — ChemoCentryx, Inc., a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing orally-administered therapeutics that target the chemokine system, today announced the appointment of Juan Jaen, Ph.D., to the position of Senior Vice President, Drug Discovery. ...
Dec 1, 2006
Miami, FL - December 1, 2006 — ChemoCentryx, Inc. is presenting clinical and preclinical data from studies of the company's drug candidate Traficet-EN® (CCX282-B) a first-in-class, orally active, anti-inflammatory agent that targets the chemokine receptor known as CCR9, at the 2006 Crohn's and Colitis Foundation of America's (CCFA...
Oct 24, 2006
Berlin, Germany — October 24, 2006 — ChemoCentryx, Inc., a clinical-stage, biopharmaceutical company developing orally-administered therapeutics that target the chemokine and chemoattractant systems, today announced positive data from the company's Phase 2 clinical trial of Traficet-EN™ (CCX282-B) for the treatment of Crohn...
Aug 24, 2006
Mountain View, CA, USA; August 24, 2006 — ChemoCentryx, Inc. today announced that it has recently completed a Series C financing in June 2006 with participating investors including Jennison Associates, HBM BioVentures, Orbimed Advisors, Techne Corporation, Alta Partners, and GIMV. Gross proceeds from this round of financing totaled $1...
Page: FirstPrevious ...
18
NextLast
= add release to Briefcase